1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Albumin Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Product
6.1 Human Serum Albumin
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Bovine Serum Albumin
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Recombinant Albumin
6.3.1 Market Trends
6.3.2 Market Forecast
7 Market Breakup by Application
7.1 Therapeutics
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Drug Formulation and Vaccine
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Component of Media
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Others
7.4.1 Market Trends
7.4.2 Market Forecast
8 Market Breakup by End User
8.1 Hospitals and Clinics
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Pharmaceutical and Biotechnology Companies
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Research Institutes
8.3.1 Market Trends
8.3.2 Market Forecast
9 Market Breakup by Region
9.1 North America
9.1.1 United States
9.1.1.1 Market Trends
9.1.1.2 Market Forecast
9.1.2 Canada
9.1.2.1 Market Trends
9.1.2.2 Market Forecast
9.2 Asia-Pacific
9.2.1 China
9.2.1.1 Market Trends
9.2.1.2 Market Forecast
9.2.2 Japan
9.2.2.1 Market Trends
9.2.2.2 Market Forecast
9.2.3 India
9.2.3.1 Market Trends
9.2.3.2 Market Forecast
9.2.4 South Korea
9.2.4.1 Market Trends
9.2.4.2 Market Forecast
9.2.5 Australia
9.2.5.1 Market Trends
9.2.5.2 Market Forecast
9.2.6 Indonesia
9.2.6.1 Market Trends
9.2.6.2 Market Forecast
9.2.7 Others
9.2.7.1 Market Trends
9.2.7.2 Market Forecast
9.3 Europe
9.3.1 Germany
9.3.1.1 Market Trends
9.3.1.2 Market Forecast
9.3.2 France
9.3.2.1 Market Trends
9.3.2.2 Market Forecast
9.3.3 United Kingdom
9.3.3.1 Market Trends
9.3.3.2 Market Forecast
9.3.4 Italy
9.3.4.1 Market Trends
9.3.4.2 Market Forecast
9.3.5 Spain
9.3.5.1 Market Trends
9.3.5.2 Market Forecast
9.3.6 Russia
9.3.6.1 Market Trends
9.3.6.2 Market Forecast
9.3.7 Others
9.3.7.1 Market Trends
9.3.7.2 Market Forecast
9.4 Latin America
9.4.1 Brazil
9.4.1.1 Market Trends
9.4.1.2 Market Forecast
9.4.2 Mexico
9.4.2.1 Market Trends
9.4.2.2 Market Forecast
9.4.3 Others
9.4.3.1 Market Trends
9.4.3.2 Market Forecast
9.5 Middle East and Africa
9.5.1 Market Trends
9.5.2 Market Breakup by Country
9.5.3 Market Forecast
10 SWOT Analysis
10.1 Overview
10.2 Strengths
10.3 Weaknesses
10.4 Opportunities
10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 Albumedix Ltd
14.3.1.1 Company Overview
14.3.1.2 Product Portfolio
14.3.2 Biotest AG
14.3.2.1 Company Overview
14.3.2.2 Product Portfolio
14.3.2.3 Financials
14.3.2.4 SWOT Analysis
14.3.3 Celgene Corporation (Bristol-Myers Squibb Company)
14.3.3.1 Company Overview
14.3.3.2 Product Portfolio
14.3.3.3 SWOT Analysis
14.3.4 CSL Limited
14.3.4.1 Company Overview
14.3.4.2 Product Portfolio
14.3.4.3 Financials
14.3.4.4 SWOT Analysis
14.3.5 Grifols SA
14.3.5.1 Company Overview
14.3.5.2 Product Portfolio
14.3.5.3 Financials
14.3.5.4 SWOT Analysis
14.3.6 HiMedia Laboratories
14.3.6.1 Company Overview
14.3.6.2 Product Portfolio
14.3.7 Medxbio Pte Ltd
14.3.7.1 Company Overview
14.3.7.2 Product Portfolio
14.3.8 Merck KGaA
14.3.8.1 Company Overview
14.3.8.2 Product Portfolio
14.3.8.3 Financials
14.3.8.4 SWOT Analysis
14.3.9 Octapharma AG
14.3.9.1 Company Overview
14.3.9.2 Product Portfolio
14.3.9.3 SWOT Analysis
14.3.10 Takeda Pharmaceutical Company Limited
14.3.10.1 Company Overview
14.3.10.2 Product Portfolio
14.3.10.3 Financials
14.3.10.4 SWOT Analysis
14.3.11 Thermo Fisher Scientific Inc.
14.3.11.1 Company Overview
14.3.11.2 Product Portfolio
14.3.11.3 Financials
14.3.11.4 SWOT Analysis
14.3.12 Ventria Bioscience Inc.
14.3.12.1 Company Overview
14.3.12.2 Product Portfolio
世界のアルブミン市場予測2023年-2028年 |
| 【英語タイトル】Albumin Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028 | |
 | ・商品コード：IMARC23FB0120 ・発行会社（調査会社）：IMARC ・発行日：2023年2月1日 ・ページ数：143 ・レポート言語：英語 ・レポート形式：PDF ・納品方法：Eメール ・調査対象地域：グローバル ・産業分野：化学 |
| Single User | USD2,999 ⇒換算￥455,848 | 見積依頼/購入/質問フォーム |
| Five User | USD3,999 ⇒換算￥607,848 | 見積依頼/購入/質問フォーム |
| Enterprisewide | USD4,999 ⇒換算￥759,848 | 見積依頼/購入/質問フォーム |
|
※販売価格オプションの説明 ※お支払金額：換算金額（日本円）＋消費税 ※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡） ※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能） |
| IMARC社は、2022年に57億ドルであった世界のアルブミン市場規模が2028年に82億ドルに達し、2023年から2028年の間に年平均6.05％成長すると予測しています。本調査レポートでは、アルブミンの世界市場を調査・分析し、序論、範囲・調査手法、エグゼクティブサマリー、イントロダクション、製品別（ヒト血清アルブミン、ウシ血清アルブミン、リコンビナントアルブミン）分析、用途別（治療薬、薬品製剤・ワクチン、媒体構成要素、その他）分析、エンドユーザー別（病院・診療所、製薬・バイオテクノロジー企業、研究機関）分析、地域別（北米、アジア太平洋、ヨーロッパ、中南米、中東・アフリカ）分析、SWOT分析、バリューチェーン分析、ファイブフォース分析、価格分析、競合状況などの項目を掲載しています。また、本調査レポートに掲載されている企業情報には、Albumedix Ltd、Biotest AG、Celgene Corporation (Bristol-Myers Squibb Company)、CSL Limited、Grifols SA、HiMedia Laboratories、Medxbio Pte Ltd、Merck KGaA、Octapharma AG、Takeda Pharmaceutical Company Limited、Thermo Fisher Scientific Inc. and Ventria Bioscience Inc.などが含まれています。 ・序論 ・範囲・調査手法 ・エグゼクティブサマリー ・イントロダクション ・世界のアルブミン市場規模：製品別 - ヒト血清アルブミンの市場規模 - ウシ血清アルブミンの市場規模 - リコンビナントアルブミンの市場規模 ・世界のアルブミン市場規模：用途別 - 治療薬における市場規模 - 薬品製剤・ワクチンにおける市場規模 - 媒体構成要素における市場規模 - その他用途における市場規模 ・世界のアルブミン市場規模：エンドユーザー別 - 病院・診療所における市場規模 - 製薬・バイオテクノロジー企業における市場規模 - 研究機関における市場規模 ・世界のアルブミン市場規模：地域別 - 北米のアルブミン市場規模 - アジア太平洋のアルブミン市場規模 - ヨーロッパのアルブミン市場規模 - 中南米のアルブミン市場規模 - 中東・アフリカのアルブミン市場規模 ・SWOT分析 ・バリューチェーン分析 ・ファイブフォース分析 ・価格分析 ・競合状況 |
The global albumin market size reached US$ 5.7 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 8.2 Billion by 2028, exhibiting a growth rate (CAGR) of 6.05% during 2023-2028.
Albumin is a water-soluble globular protein present in blood plasma. It is synthesized in the liver and is essential for maintaining the blood volume and transportation of enzyme, hormone and bile salt molecules. It is commonly available in human, bovine and recombinant variants. They are crucial for sustaining the intravascular colloid osmotic pressure (COP) and preventing leakage of fluids into the tissue. It is commonly used as a blood volumizer for the treatment of rare diseases, burns, liver disorders, blood loss trauma and surgical complications. It is also utilized in pharmaceutical drugs for stabilization, enhancing surface absorption and reducing aggregation and oxidation. As a result, albumin finds extensive application in the manufacturing of drug delivery systems, therapeutics, culture media and vaccines.
Albumin Market Trends:
The increasing prevalence of chronic medical ailments across the globe is one of the key factors driving the growth of the market. Albumin is widely used in the treatment of hypovolemia, acute respiratory distress syndrome, nephrosis, renal dialysis, liver failure, cardiopulmonary disorders and hypoalbuminemia. Moreover, the rising geriatric population, which is more susceptible to such ailments is providing a thrust to the market growth. Additionally, the widespread adoption of human serum albumin (HSA) for replenishing proteins in human plasma and maintaining plasma colloid oncotic pressure is acting as another growth-inducing factor. It also aids in preventing the denaturation of active protein ingredients, thereby making it highly beneficial for the production of vaccines. Other factors, including the introduction of albumin-based nanoparticles, along with extensive research and development (R&D) activities in the field of biotechnology, are anticipated to drive the market toward growth.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global albumin market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on product, application and end user.
Breakup by Product:
Human Serum Albumin
Bovine Serum Albumin
Recombinant Albumin
Breakup by Application:
Therapeutics
Drug Formulation and Vaccine
Component of Media
Others
Breakup by End User:
Hospitals and Clinics
Pharmaceutical and Biotechnology Companies
Research Institutes
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Albumedix Ltd, Biotest AG, Celgene Corporation (Bristol-Myers Squibb Company), CSL Limited, Grifols SA, HiMedia Laboratories, Medxbio Pte Ltd, Merck KGaA, Octapharma AG, Takeda Pharmaceutical Company Limited, Thermo Fisher Scientific Inc. and Ventria Bioscience Inc.
Key Questions Answered in This Report
1. What was the size of the global albumin market in 2022?
2. What is the expected growth rate of the global albumin market during 2023-2028?
3. What are the key factors driving the global albumin market?
4. What has been the impact of COVID-19 on the global albumin market?
5. What is the breakup of the global albumin market based on the product?
6. What is the breakup of the global albumin market based on the application?
7. What is the breakup of the global albumin market based on end user?
8. What are the key regions in the global albumin market?
9. Who are the key players/companies in the global albumin market?
❖ レポートの目次 ❖
| ★調査レポート[世界のアルブミン市場予測2023年-2028年] (コード：IMARC23FB0120)販売に関する免責事項を必ずご確認ください。 |
| ★調査レポート[世界のアルブミン市場予測2023年-2028年]についてメールでお問い合わせ |
